دورية أكاديمية
أعرض في EDS

Effect of Gum Arabic on plaque-induced gingivitis: A randomised controlled trial.

التفاصيل البيبلوغرافية
العنوان: Effect of Gum Arabic on plaque-induced gingivitis: A randomised controlled trial.
المؤلفون: Gafar AM; Sudan Medical Specialisation Board, Khartoum, Sudan., Ramadan AM; Ibn Sina National College, Saudi Arabia., ElSaid NA; Toronto, Canada., Nurelhuda NM; Faculty of Dentistry, University of Khartoum, Sudan.
المصدر: The Saudi dental journal [Saudi Dent J] 2022 Sep; Vol. 34 (6), pp. 494-502. Date of Electronic Publication: 2022 Jun 13.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Saudi Dental Society Country of Publication: Saudi Arabia NLM ID: 9313603 Publication Model: Print-Electronic Cited Medium: Print ISSN: 1013-9052 (Print) Linking ISSN: 10139052 NLM ISO Abbreviation: Saudi Dent J Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Riyadh : Saudi Dental Society, 1989-
مستخلص: New approaches to treating periodontal diseases aim to balance sustaining the natural oral microbiota and modifying the host immune response. Gum Arabic (GA) is a natural polysaccharide rich in prebiotics.The aim of this study was to assess the effect of GA on clinical (Plaque Index (PI), Gingival Index (GI)) and immunological (Gingival Crevicular Fluid Interleukin 1 Beta (GCF IL-1 β)) parameters in patients with plaque-induced gingivitis.
Materials and Methods: This placebo-controlled, double-blinded randomised clinical trial was conducted at the Department of Periodontology at Khartoum Dental Teaching Hospital, Khartoum, Sudan, from July to October 2016. Patients diagnosed with plaque-induced gingivitis meeting the study eligibility criteria were enrolled. At baseline, PI, GI and GCF IL-1β were measured. Patients received full-mouth scaling and were randomly assigned to receive either GA powder (intervention group) or Microcrystalline cellulose powder (placebo group). The patients were instructed to apply the treatment twice a day throughout the study. The PI, GI and GCF IL-1β were reassessed after 30 and 60 days.
Results: A total of 60 patients were enrolled (30 in each group). Compared to the placebo group, the intervention group showed a statistically significant reduction in GI scores after 30 days and improved PI scores at 30 and 60 days. Between baseline and 60 days, patients who received GA exhibited a significant reduction in GCF IL-1β levels compared to the placebo group.
Conclusion: GA was found to be effective in controlling plaque and gingivitis. Clinical Trial Registration. ISRCTN registry ISRCTN14209449.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2022 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University.)
References: J Biochem Mol Toxicol. 2003;17(3):146-53. (PMID: 12815610)
J Dent Res. 1993 Aug;72(8):1194-7. (PMID: 8360362)
Aust Dent J. 2012 Sep;57(3):312-8. (PMID: 22924354)
J Clin Periodontol. 2002 Jan;29(1):48-53. (PMID: 11846849)
Saudi Dent J. 2018 Jan;30(1):53-62. (PMID: 30166872)
Food Chem Toxicol. 2009 Jan;47(1):1-8. (PMID: 18672018)
Front Biosci. 2008 Jan 01;13:966-84. (PMID: 17981604)
J Indian Soc Periodontol. 2008 Sep;12(3):79-83. (PMID: 20142950)
J Clin Periodontol. 2012 Mar;39(3):295-302. (PMID: 22126282)
J Periodontol (1930). 1965 May-Jun;36:177-87. (PMID: 14296927)
J Oral Microbiol. 2009 May 01;1:. (PMID: 21523212)
Chin J Dent Res. 2012;15(1):49-53. (PMID: 22866283)
J Periodontal Res. 1993 Jul;28(4):241-7. (PMID: 8101565)
J Clin Periodontol. 1993 Apr;20(4):238-43. (PMID: 8473532)
Aust Dent J. 2010 Mar;55(1):65-9. (PMID: 20415914)
J Appl Oral Sci. 2009 Sep-Oct;17(5):404-7. (PMID: 19936516)
Acta Odontol Scand. 1963 Dec;21:533-51. (PMID: 14121956)
J Clin Periodontol. 2011 Mar;38 Suppl 11:159-77. (PMID: 21323712)
Front Immunol. 2020 Jan 31;10:3119. (PMID: 32082302)
Clin Microbiol Rev. 2003 Oct;16(4):658-72. (PMID: 14557292)
J Periodontol. 1984 Dec;55(12):684-8. (PMID: 6394735)
Inflamm Res. 2009 May;58(5):277-83. (PMID: 19184351)
mSphere. 2021 Aug 25;6(4):e0016221. (PMID: 34287005)
Acta Odontol Scand. 2003 Aug;61(4):193-6. (PMID: 14582585)
Oxid Med Cell Longev. 2009 Sep-Oct;2(4):207-13. (PMID: 20716906)
J Clin Periodontol. 2016 Sep;43(9):727-45. (PMID: 27027257)
J Clin Periodontol. 2017 May;44(5):456-462. (PMID: 28419559)
Ren Fail. 2004 Jan;26(1):1-3. (PMID: 15083914)
Oral Dis. 2000 May;6(3):138-51. (PMID: 10822357)
Br J Nutr. 2008 Dec;100(6):1269-75. (PMID: 18466655)
Afr J Tradit Complement Altern Med. 2009 May 07;6(3):228-32. (PMID: 20448847)
J Nutr. 1995 Jun;125(6):1401-12. (PMID: 7782892)
Acta Odontol Scand. 1964 Feb;22:121-35. (PMID: 14158464)
Int J Oral Sci. 2020 Jan 2;12(1):2. (PMID: 31900383)
Pharmacol Res. 2003 Dec;48(6):631-5. (PMID: 14527829)
Drug Metab Rev. 2004 Oct;36(3-4):805-22. (PMID: 15554248)
J Biochem Mol Toxicol. 2002;16(5):254-9. (PMID: 12439867)
J Clin Periodontol. 1991 Jan;18(1):75-7. (PMID: 2045522)
Naunyn Schmiedebergs Arch Pharmacol. 2020 Aug;393(8):1427-1436. (PMID: 32157347)
Int J Rheumatol. 2018 Jul 05;2018:4197537. (PMID: 30112005)
BMC Oral Health. 2012 Feb 24;12:5. (PMID: 22364514)
فهرسة مساهمة: Keywords: Antimicrobial; Chemical plaque control; Clinical trial; Gingivitis; Gum Arabic
تواريخ الأحداث: Date Created: 20220912 Latest Revision: 20220913
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC9453537
DOI: 10.1016/j.sdentj.2022.06.002
PMID: 36092515
قاعدة البيانات: MEDLINE
الوصف
تدمد:1013-9052
DOI:10.1016/j.sdentj.2022.06.002